Cargando…
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
A growing number of human tumor antigens have been described that can be recognized by cytotoxic T lymphocytes (CTLs) in a major histocompatibility complex (MHC) class I–restricted fashion. Serological screening of cDNA expression libraries, SEREX, has recently been shown to provide another route fo...
Autores principales: | Jäger, Elke, Chen, Yao-Tseng, Drijfhout, Jan W., Karbach, Julia, Ringhoffer, Mark, Jäger, Dirk, Arand, Michael, Wada, Hisashi, Noguchi, Yuji, Stockert, Elisabeth, Old, Lloyd J., Knuth, Alexander |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212106/ https://www.ncbi.nlm.nih.gov/pubmed/9432985 |
Ejemplares similares
-
Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000) -
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
por: Stockert, Elisabeth, et al.
Publicado: (1998) -
Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022) -
NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012) -
Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity
in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)